PTHS

Pelthos Therapeutics Inc. (PTHS) is a biotechnology company within the healthcare sector. With a market capitalization of $82.69M and revenue of $7.41M (TTM), it operates on a relatively small scale compared to larger industry players. The company's financial health is marked by significant losses, with a net income of -$23,581,338 (TTM) and free cash flow of -$20,788,272. Its profitability metrics are also concerning, with operating margin at -207.4% and profit margin at 0.0%. On the other hand, it has managed to maintain positive gross margins at 69.3%. The balance sheet shows a relatively low level of debt ($3.48M) compared to cash reserves ($14.20M), resulting in a debt-to-equity ratio of 5.97. The company's valuation metrics are as follows: Price to Book at 1.42, and Price to Sales at 11.17. The forward P/E ratio stands at -4.40, indicating that the market is currently expecting significant losses for the next period. There is no dividend information available, and revenue growth rates are not provided in the available data.